Streetbeat News

Price Targets

RCL

Analyst ratings for Royal Caribbean Gr (NYSE:RCL) show a mix of bullish to bearish sentiments. Over the last quarter, 10 analysts provided ratings with 5 bullish, 3 somewhat bullish, and 2 indifferent. The 12-month price targets have an average of $123.0, with a high of $155.00 and a low of $95.00, reflecting a slight increase from the previous average of $122.43. Recent analyst actions include adjustments to ratings and price targets, with some maintaining their positions while others raise or lower their targets. Royal Caribbean operates 64 ships and has 10 more on order, with a market cap above industry average, a revenue growth rate of 39.0%, a net margin of 24.25%, but an ROE and ROA below industry standards, and a debt-to-equity ratio of 4.65.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 12:01 pm

CRWD

CrowdStrike Holdings (NASDAQ:CRWD) has received 37 analyst ratings in the past three months, with a consensus leaning towards bullish. The average 12-month price target is $231.35, up from $207.04, with a high estimate of $325.00 and a low of $180.00. Analysts from firms like Needham, BMO Capital, and Goldman Sachs have raised their price targets, reflecting positive sentiment towards CRWD's financial performance, including strong revenue growth and net margin, despite a lower ROE and market capitalization below industry benchmarks.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 12:00 pm

GKOS

Analysts have provided varied ratings for Glaukos (NYSE:GKOS) over the last quarter, with recent updates showing an average 12-month price target of $80.86, up from the previous $75.25. The highest target is $91.00 and the lowest is $65.00. Analyst actions include ratings from 'Overweight' to 'Neutral' and price target adjustments. Glaukos is an ophthalmic medical technology company with products like iStent. Despite positive revenue growth, the company's market capitalization, net margin, ROE, and ROA are below industry averages, although it has a sound debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 12:00 pm

AMZN

Analyst ratings for Amazon.com (NASDAQ:AMZN) show a mix of bullish and somewhat bullish perspectives with no bearish or indifferent ratings. Over the last three months, 32 analysts have provided ratings, with recent updates indicating a slight increase in the 12-month price target average to $174.28. Analysts from firms like Wedbush, Oppenheimer, and Truist Securities have raised their price targets, while others have maintained their positive outlook. Amazon's strong financial performance is highlighted by its market capitalization, revenue growth, net margin, ROE, ROA, and a conservative debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 12:00 pm

PODD

Insulet (NASDAQ:PODD) has been analyzed by 7 analysts, showing a range of opinions. The average 12-month price target is $213.29, with a high of $250 and a low of $162, marking a 13.71% decrease in the average target. Analysts from firms like Baird, Morgan Stanley, Piper Sandler, JP Morgan, Leerink Partners, and Jefferies have adjusted their ratings and price targets. Insulet's financials show strong revenue growth and ROE, but a high debt-to-equity ratio and below-average net margin.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 12:00 pm

ANNX

Needham analyst Joseph Stringer has reiterated a Buy rating on Annexon (NASDAQ:ANNX) and maintained a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 12:00 pm

MYGN

Four financial analysts have provided diverse ratings for Myriad Genetics (NASDAQ:MYGN) over the last three months, with a shift towards a more positive outlook in the last 30 days. The average 12-month price target for MYGN has increased by 17.65% to $20.00, with a high estimate of $23.00 and a low of $14.00. Myriad Genetics is a molecular diagnostics company with recent positive revenue growth but faces challenges with net margin, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 12:00 pm

LLY

Daiwa Capital analyst has downgraded Eli Lilly (NYSE:LLY) from Buy to Outperform while setting a price target of $610.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 11:52 am

HIW

Morgan Stanley analyst Ronald Kamdem has downgraded Highwoods Properties (HIW) from Equal-Weight to Underweight and reduced the price target from $22 to $18.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 11:49 am

SPG

Morgan Stanley analyst Ronald Kamdem has downgraded Simon Property Group (NYSE:SPG) from Overweight to Equal-Weight while increasing the price target from $132 to $143.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 11:47 am